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SHORT REPORT
Vaccination against pancreas disease 
in Atlantic salmon, Salmo salar L., reduces 
shedding of salmonid alphavirus
Pål Skjold1* , Ingunn Sommerset2, Petter Frost1 and Stephane Villoing1
Abstract 
Salmon pancreas disease virus, often referred to as salmonid alphavirus (SAV), causes pancreas disease (PD) in Euro-
pean salmonids. SAV transmits horizontally from fish shedding virus into the water and ocean currents are believed 
to be a main contributor of viral spread between marine farms. Vaccination against PD is previously shown to reduce 
mortality and severity of clinical PD. In this study, we demonstrate that vaccination against PD significantly reduces 
viral shedding from infected individuals. The results suggest that PD vaccination can be an important tool to reduce 
the infection pressure, a known key risk for PD outbreaks at neighbouring farms.
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provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction, methods and results
Salmon pancreas disease virus (SPDV), hereafter referred 
to as salmonid alphavirus (SAV) [1], is a highly contagious 
virus and the aetiological agent of pancreas disease (PD) 
in marine reared Atlantic salmon (Salmo salar) and rain-
bow trout (Oncorhynchus mykiss) [2, 3], and referred to as 
sleeping disease (SD) in freshwater reared rainbow trout 
[4]. Horizontal transmission of SAV has been shown in 
both fresh- and seawater in experimental trials [5, 6] and 
experimental challenges have shown that viral shedding 
typically precedes clinical PD [7, 8]. When clinical PD 
results in mortality, release of infective virions may also 
occur from dead fish being subjected to degradation [9]. 
Current knowledge emphasizes horizontal transmission 
of SAV by ocean currents in the seawater phase as a main 
contributor of viral spread within and between farms 
[10–12]. Hydrodynamic models have been used as a tool 
to explain the spreading patterns of SAV in fjord systems, 
and water contact between farms has been pointed out 
to be the variable that correlates best with field observa-
tions of PD-outbreaks in time and space [11, 12]. Vacci-
nation against PD has been shown to reduce the number 
of outbreaks, cumulative mortality and downgrading at 
slaughter [13], i.e. reducing the disease severity, although 
the complete nature of the immune response leading to 
the observed vaccine efficacy is not known. Both faeces 
and mucus have been shown to be involved in the shed-
ding of SAV from diseased salmon in experimental trials 
[8, 14]. Furthermore, analyses of water samples collected 
during SAV experimental challenge have shown that viral 
shedding from SAV infected fish coincides with the infec-
tion stage when SAV is present in the blood, i.e. during 
viraemia [7], which occurs prior to histopathological 
changes in the heart [15]. However, no published stud-
ies exist on viral shedding following SAV challenge of 
PD vaccinated fish. In the current study, we performed 
a SAV challenge trial where we compared SAV shedding 
from PD vaccinated versus unvaccinated fish. Presence of 
SAV was analysed in water samples collected from tanks 
containing either vaccinated or unvaccinated Atlantic 
salmon following challenge with a Norwegian SAV iso-
late. In addition, untreated Atlantic salmon were added 
to each tank as “detectors” for the presence of infectious 
SAV in the water. The animal trial design is outlined in 
Figure 1.
This animal trial was approved by the Norwegian Ani-
mal Research Authority (FOTS ID 6100) and carried out 
at The Industrial and Aquatic Laboratory (ILAB) wet lab 
facilities at the Bergen High Technology Centre, Norway. 
The fish population (Atlantic salmon Salmobreed strain) 
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had been pretested for infectious pancreatic necrosis 
virus (IPNV), piscine orthoreovirus, infectious salmon 
anaemia virus (ISAV) and SAV by means of real-time 
RT-PCR (hereafter referred to as qRT-PCR) analysis 
provided by Patogen Analysis AS (Ålesund, Norway), 
and found negative. A total of 260 Atlantic salmon parr 
with an average weight of 30 grams were anaesthetised 
with FINQUEL® Vet. (ScanAqua AS, Årnes, Norway) 
according to manufacturer’s recommendations. 130 fish 
were vaccinated with AQUAVAC® PD7 (0.1  mL/fish), a 
commercial heptavalent vaccine containing 5 inactivated 
bacterial antigens (Aeromonas salmonicida subsp. sal-
monicida, Vibrio salmonicida, Vibrio anguillarum sero-
type O1 and O2a, Moritella viscosa) and 2 inactivated 
viral antigens (IPNV and SAV) in a mineral oil emul-
sion. As unvaccinated controls, a total of 130 fish were 
injected intraperitoneally with sterile saline solution 
(0.9% NaCl, 0.1 mL/fish). The PD vaccinated and unvac-
cinated groups were kept in individual 500 L tanks with 
12 °C flow through fresh water for 6 weeks post vaccina-
tion (~500 degree-days) before 120 fish from each group 
were challenged intramuscularly with 2.05 log10 TCID50/
fish (0.05 mL/fish) of a Norwegian SAV isolate (SAV gen-
otype 3) propagated in Chinook salmon embryo (CHSE-
214) cell culture. The fish were, while being challenged, 
allocated to four 150 L challenge tanks (tank 1 to 4), gen-
erating duplicate tanks with 60 fish for both vaccinated 
and unvaccinated groups. The water flow in the tanks 
was 300 L per hour.
The remaining 20 fish (10 from the AQUAVAC® PD7 
vaccinated group and 10 from the unvaccinated controls) 
were labelled by maxillae clipping, challenged using the 
same procedure as above and allocated in one 500 L tank 
(tank 5) in order to estimate the prevalence of infected 
individuals in the two groups. These 20 fish were sampled 
for blood and faeces 10 days post challenge (dpc) which 
by our experience corresponds to the peak viraemia time 
point following intramuscular (i.m.) challenge with SAV 
at 12 °C.
One day post i.m. challenge, 10 untreated, naïve cohab-
itants were labelled by adipose fin clipping and added 
to tank 1–4 as “detectors” of infectious SAV shed from 
the challenged fish already present in the tank. These 40 
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Figure 1 Illustration of the experimental setup. 130 Atlantic salmon were vaccinated with AQUAVAC® PD7 into a 500 L tank with flow through 
freshwater at 12 °C (PD vacc.). As controls, 130 Atlantic salmon were injected with a sterile saline solution and put in a separate tank with same 
conditions (Un vacc.). Six weeks post vaccination (wpv ≈ 500 degree-days), intramuscular challenge with a Norwegian SAV isolate was performed. 
Following challenge, 120 fish from each group were allocated in duplicate tanks holding 60 vaccinated or unvaccinated fish each (tanks 1–4). The 
remaining 10 fish from each group were mixed in a separate tank (tank 5). Water samples (WS) were collected from tanks 1–4 at day 1, 4, 10, 14, 18 
and 24 post challenge. 1 day post challenge (dpc), naïve cohabitants were added to tanks 1–4 (n = 10 per tank). Serum was sampled from the naïve 
cohabitants 24 dpc. 10 days post challenge, serum and faeces were sampled from all fish in tank 5 (n = 10 per group).
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which, by our experience, corresponds to the peak virae-
mia time point following cohabitation challenge with 
SAV at 12 °C.
Water samples from tanks 1–4 were collected 1, 4, 10, 
14, 18 and 24 days post challenge using sterile 1 L screw-
cap PET bottles (VWR). All samples were vacuum filtered 
through electropositive Zeta Plus® Virosorb® 1 MDS fil-
ters (Cuno Inc., USA) according to a method described 
in Andersen et  al. [7] with minor modifications. Imme-
diately following sampling and prior to filtration each 
water sample was spiked with 50  μL (5.2 log10 TCID50) 
of an ISAV isolate (Bremnes/98) which was used as an 
exogenous filtration control and for the relative quanti-
fication of SAV in the water samples. One litre of filtered 
and deionized water (Milli-Q®, Millipore Corporation), 
spiked with the same volume of the ISAV suspension, was 
also subjected to filtration at all sampling points in order 
to check for potential cross-contamination between 
water samples. After filtration, individual filters were 
soaked in 1.4  mL lysis buffer (RNeasy® 96 Kit, Qiagen) 
for 10 min on a rocker (320 rpm), and 2 × 350 μL (A and 
B sample) were collected and frozen at −80 °C for subse-
quent RNA extraction and qRT-PCR analysis. The water 
samples were analysed by qRT-PCR in triplicate, using 
the SAV nsP1 [16] and ISAV segment 8 (S8) [17] assays 
for specific detection of SAV and ISAV, respectively. Only 
samples that were positive in triplicate were used for 
normalization performed as described elsewhere [7, 18]. 
During qRT-PCR setup, positive, negative and no tem-
plate controls (NTC) were included in all runs. Mean Ct 
values (Cycle threshold) for the nsP1 assay were normal-
ized against mean Ct values for the ISAV S8 assay using 
the Microsoft® Excel based software Q-Gene with Eq. 2 
[19]. Mean normalized expression (MNE) values were 
transformed into fold change by calibrating against the 
lowest MNE value obtained from water samples during 
the experiment for a better visualization of the data. The 
cross-contamination controls (pre-filtered and deionized 
Milli-Q® water) were all negative for SAV and positive for 
ISAV by qRT-PCR analysis at all sampling points.
Serum (50 μL/fish) and faeces samples (2 × 2 × 2 mm/
fish) were spiked with inactivated Equine Influenza 
Virus (EIV) prior to RNA extraction, serving as an exog-
enous RNA extraction control and for relative quantifi-
cation of SAV RNA eventually present in the samples. 
These samples were analysed by qRT-PCR using the EI 
H3 assay targeting EIV [20], and the nsP1 assay target-
ing SAV. Normalised expression (NE) values obtained 
from serum and faeces were fold changed by calibrat-
ing against the lowest NE value obtained for each tissue 
and log2 transformed for a better visualization of the 
data. RNA from serum, faeces and water samples was 
extracted using the RNeasy® 96 Kit (Qiagen) according 
to the manufacturer’s protocol (elution volume was 50 
μL/RNA sample). qRT-PCR analyses were performed 
using Verso™ 1-step Q-RT-PCR Kit low ROX (Thermo 
Scientific) using 4 μL of RNA sample. Primer and probe 
concentrations for each of the three assays were: Fwd. 
primer: 900 nM, Reverse primer: 900 nM, Probe: 260 nM. 
Reactions were run in an ABI PRISM® 7500 FAST Ther-
mocycler from Applied Biosystems at the following 
conditions: 50  °C/30  min, 95  °C/15  min, 40 cycles of 
95 °C/15 s and 60 °C/60 s. Standard curve was generated 
for each assay from dilution series of SAV, ISAV and EIV 
in Phosphate-buffered saline (PBS). Slope, R2 and assay 
efficiency were calculated for each assay using Q-Gene 
giving the following values (SAV nsP1/ISAV S8/EI H3): 
−3.1685/−3.8113/−3.4403 (slope), 0.9964/0.9992/0.9976 
(R2) and 2.0683/1.8297/1.9529 (E).
Statistical analysis of the effect of PD vaccination on 
the viral load in the water samples detected by qRT-PCR 
was performed using the Pair Wise Fixed Reallocation 
Randomisation Test implemented in the program REST 
2009 [21], using as input the mean Ct values of triplicate 
measurements on each sample for SAV nsP1 assay (tar-
get gene), the mean Ct values for the ISAV spike obtained 
with ISAV S8 assay (reference gene) and the PCR efficien-
cies of these assays.
Statistical analysis of the effect of PD vaccination on 
the prevalence of PCR positive fish in serum of the naïve 
cohabitant fish at 24 dpc was performed using a General-
ized Linear Mixed Model (GLMM) for a binomial distri-
bution (SAS procedure GLIMMIX), on the prevalence of 
positive fish in each tank, including tank as random effect 
to account for the correlation in the data.
Statistical analysis of the effect of PD vaccination on 
the viral load detected by qRT-PCR in the serum sampled 
from the naïve fish was performed using the Pair Wise 
Fixed Reallocation Randomisation Test implemented in 
REST 2009, using as input the individual Ct values for 
SAV nsP1 assay (target gene), the individual Ct values for 
the EIV spike obtained with EI H3 assay (reference gene) 
and the PCR efficiencies of these assays. The Ct values 
used for the analysis in REST 2009 were censored, i.e. 
the negative samples (with undetermined SAV Ct values) 
were assigned a Ct  =  40 (=max number of cycles per 
PCR run).
Statistical comparison of the prevalence of SAV posi-
tive fish in tank 5 (detected by RT-PCR on serum and 
faeces samples) between vaccinated and unvaccinated 
groups was performed by the Fisher’s exact test. Relative 
Risks were used to determine Relative Percentage Protec-
tion [RPP = (1−RR) × 100] as a measure of the vaccine’s 
efficacy.
For all statistical analysis the level of significance (α) 
was set at 0.05 and tests were two-sided. Statistical 
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calculations were executed using REST 2009 for the Fixed 
Reallocation Randomisation Test (set to 2000 iterations), 
SAS V9.3 for GLMM and SAS Enterprise Guide V7.1 for 
Fisher test (SAS Institute Inc. Cary NC, USA).
The ISAV qRT-PCR analysis showed that all water 
samples were positive for the ISAV spike, demonstrating 
successful filtration and RNA extraction. SAV mean nor-
malized expression (MNE) values from the water sam-
ples (1–24 dpc) are presented in Figure  2. In the water 
of the two duplicate tanks containing the PD vaccinated 
and SAV challenged fish (1 and 2) no SAV was detected 
at any of the six sampling points from 1 to 24 dpc. In the 
water of the two duplicate tanks containing the unvacci-
nated and SAV challenged fish (tanks 3 and 4) SAV was 
detected in the water at 14 and 24 dpc (tank 3) and at 10, 
14 and 24 dpc (tank 4). SAV could not be detected in any 
of the unvaccinated group tanks at 1, 4 and 18 dpc. Statis-
tical analysis of the PCR data obtained for the water sam-
ples showed that PD vaccination significantly reduced 
the SAV viral load in the water (p = 0.014).
Among the 10 naïve cohabitants added to each tank 
as “detectors” for infectious SAV in the water, low levels 
of SAV was detected in serum of 2 and 4 fish from tanks 
1 and 2, respectively (PD vaccinated fish) while 10 and 
8 fish from tanks 3 and 4 (unvaccinated) were positive, 
respectively (Figure  3). Statistical analysis of the preva-
lence of PCR positive among the naïve cohabitant fish 
at 24 dpc showed that there was a significant reduction 
(p =  0.0065) of the prevalence of PCR positives among 
the naïve fish added to tanks containing PD vaccinated 
fish compared to the tanks containing unvaccinated fish. 
Statistical analysis of the SAV Ct values obtained for the 
naïve cohabitant fish at 24 dpc showed that there was a 
significant reduction (p < 0.0001) of the SAV viral load in 
the naïve fish added to tanks containing PD vaccinated 
fish compared to the tanks containing unvaccinated fish.
In tank 5 containing the mixed challenge control 
groups, 2 of the 10 PD vaccinated fish were positive for 
SAV in serum, while none of the same individuals were 
positive in faeces 10  days after the SAV i.m. challenge 
(Figure 4). In the unvaccinated fish in the same tank, 10 
out of 10 fish were positive for SAV in serum, while 7 
out of 10 fish also tested positive for SAV in faeces. Sta-
tistical analysis of the PCR data obtained for the fish in 
tank 5 showed that PD vaccination significantly reduced 
the viral load in serum and faeces with RPP  =  80% 
(p = 0.0007) and RPP = 100% (p = 0.0031), respectively.
Discussion
In this study, we demonstrated that following experi-
mental challenge, PD vaccinated Atlantic salmon shed 
significantly lower levels of SAV into the water com-
pared to unvaccinated fish. The experimental challenge 
was done by injection (i.m.) to: (1) avoid possible conflict 
with waterborne challenge material present in a cohabi-
tation model, (2) have a simultaneous and controlled 
infection in all test animals, and (3) administer infec-
tive virions to muscle/blood stream to avoid possible 
non-specific protection in the intraperitoneal cavity due 
to the i.p. vaccination. However, i.m. injection of SAV 
is probably a severe challenge, as all natural barriers are 
bypassed and infective virions quickly enter the blood 
stream to give a rapid systemic infection. SAV challenge 
by i.m. injection is not the natural route, but its suitabil-
ity to assess vaccine efficacy has been established [22]. In 
the water samples collected at six time points between 
Unvaccinated
(tank 4)




















Figure 2 Relative quantification of SAV in water samples from tanks containing PD vaccinated or unvaccinated fish. Fold changed 
mean normalized expression (MNE) values from Ct values obtained from water samples by qRT-PCR. Ct values (mean of triplicate) obtained for the 
nsP1 assay (target) were normalized against Ct values obtained for the ISAV spike (reference). Subsequently, all MNE values were calibrated against 
the lowest MNE value obtained from water samples (fold change). Tanks 1 and 2 contained AQUAVAC® PD7 vaccinated fish (n = 60 per tank), while 
tanks 3 and 4 contained unvaccinated fish (n = 60 per tank). All four tanks contained naïve cohabitants (n = 10 per tank) from 1 dpc.
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1 and 24  days post challenge, SAV could, by qRT-PCR, 
not be detected in either of the two duplicated tanks 
containing PD vaccinated fish (Figure 2), while all water 
samples were positive for the ISAV spike confirming 
valid sample preparation. In the tanks containing unvac-
cinated fish, SAV was detected in one or both tanks at 
10, 14 and 24 days post challenge but not at 1, 4 and 18 
dpc. Andersen et al. [7] showed that in water samples col-
lected from tanks containing SAV i.p. injected fish, SAV 
was detected at day 4, 6, 8, 10 and 13 but not at any later 
sampling points. As evident from the current study, peak 
SAV detection in water is somewhat delayed compared 
to Andersen et al. [7]. In our experience, this is a differ-
ence typically seen for i.m. challenge versus i.p. challenge 
(unpublished). The observed SAV detection kinetics in 
water is as expected except for the re-occurrence of SAV 
in tanks 3 and 4 (unvaccinated fish) at day 24. The re-
occurrence of SAV in these tanks is probably due to virus 
shed from the naïve fish added to the tanks as “detec-
tors”. These untreated, naïve fish have been exposed to 
infective virions shed from the injected fish, correspond-
ing to a classical cohabitant challenge set-up. The time 
point, 24  days post i.m. challenge of the donor fish and 
23 days after adding the naïve fish, corresponds well with 
expected peak of viraemia (and peak of shedding) fol-
lowing cohabitation challenge at 12 °C [8, 14]. Although, 
by qRT-PCR, no SAV was detected in any of the water 
samples from the two tanks containing PD vaccinated 
fish, some naïve fish added to the tanks were infected 
(Figure 3). Relatively low concentrations (undetectable by 
current qRT-PCR method) of infectious SAV must have 
been present in these two tanks resulting in SAV being 
detected at low levels in 20 and 40% of the naïve cohab-
itants at 24 dpc (Figure  3). In comparison, high quanti-
ties of SAV (approx. 212.5 fold increase between naïve fish 
cohabitating PD vaccinated and unvaccinated fish) was 
detected in 100 and 80% of the naïve fish added to the 
two tanks containing unvaccinated, i.m. challenged fish. 
Considering the vaccine efficacy evident in tanks 1 and 2 
following i.m. challenge, it is reasonable to presume that 
if the cohabitants added to these tanks had been PD vac-
cinated, they would have been protected against this low 
infection pressure. The results also indicate that a low 
concentration of infective SAV in the water (undetectable 
by current qRT-PCR method) is sufficient to infect naïve 
fish, even when kept under optimal laboratory rearing 
conditions (low fish density, optimal O2/water flow etc.).
In the field, SAV infection pressure and infected neigh-
bouring sites are known to be key risk factors for clini-
cal PD [10, 11]. Infectious SAV has been reported to 
have a half-life of 1 day at 10 °C in seawater [23], conse-
quently giving the high potential for SAV to spread by 
passive drift in ocean currents [11, 12]. Adding to this 
risk is the fact that initial SAV infection happens unno-
ticed since shedding of SAV from infected animals starts 
a few weeks after viral exposure [8, 14], while time from 
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Figure 3 Relative quantification of SAV in serum of naïve 
cohabitants 24 days post challenge. Log2 of fold changed 
normalized expression (NE) values from positive, naïve cohabit-
ants (added 1 dpc) for SAV detected by qRT-PCR in serum at 24 dpc 
(n = 10 per tank). SAV nsP1 assay normalized against the exogenous 
spike EIV assay. NE values are calibrated against the lowest NE value 
obtained from serum during the experiment and Log2 transformed. 
Prevalence of positive in each group is shown in fractions. Median 
values are shown as horizontal lines. In tanks 1 and 2, naïve fish 
cohabitated AQUAVAC® PD7 vaccinated fish (n = 60), while in tanks 3 
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Figure 4 Relative quantification of SAV in serum and faeces 
from i.m. challenged PD vaccinated or unvaccinated fish. Log2 
of fold changed normalized expression (NE) values of SAV detected 
by qRT-PCR in faeces and serum from AQUAVAC® PD7 vaccinated 
and unvaccinated fish from tank 5. SAV nsP1 assay was normalized 
against the exogenous spike EIV assay (n = 10 per group). NE values 
are calibrated against the lowest NE value obtained from each tissue 
during the experiment and Log2 transformed. Prevalence of posi-
tive samples in each group is shown in fractions. Median values are 
shown by horizontal lines. Faeces and serum samples were collected 
10 days post i.m. challenge.
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infection to clinical disease, the typical indicator for man-
agement actions, can be several months [24]. Under field 
conditions, clinical PD typically emerges in cage after 
cage within a farm with mortality ongoing up to several 
months post clinical PD diagnosis [24]. Unlike what is 
observed in laboratory experiments, individuals within a 
fish population at a farm will not be infected at the same 
time. It is therefore likely that a farm population will shed 
SAV to the water for a longer time period thus adding to 
the infection pressure within the farm and increasing the 
probability of transferring SAV to neighbouring sites [10, 
11], or beyond by human transport activity.
In conclusion, the present study demonstrates that 
PD vaccination results in a significant decrease in shed-
ding of SAV to the water if the vaccinated fish become 
infected. In addition to the PD vaccine efficacy, by means 
of reduction of disease severity and mortality [13], this 
vaccine effect can play a major role in reducing the SAV 
infection pressure within and between farms.
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